Cinumercept for Multiple System Atrophy (NCT04449485)

Overview

Overview

Cinumercept (also known as BNC271) is a humanized monoclonal antibody specifically designed to target and clear aggregated alpha-synuclein. Developed through a collaboration between Biogen and UCB Pharma, this therapeutic candidate represents a novel approach to disease modification in Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia.

The AMBAR (Anti-alpha-Synuclein Monoclonal Antibody in Multiple System Atrophy) study was a pivotal Phase 2 clinical trial (NCT04449485) that evaluated the safety, tolerability, and efficacy of cinumercept in patients with clinically diagnosed probable MSA [@cinumercept_trial]. The trial completion in 2024-2025 marked an important milestone in the development of immunotherapeutic approaches for synucleinopathies, representing one of the most comprehensive evaluations of antibody-based alpha-synuclein targeting in this patient population.

Study Design and Methodology

Trial Overview

| Parameter | Value |
|------------|-------|
| NCT Number | NCT04449485 |
| Official Title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cinumercept in Patients With Multiple System Atrophy |
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Biogen Idec Ltd. / UCB Pharma |
| Study Type | Interventional |
| Allocation | Randomized, double-blind, placebo-controlled |
| Enrollment | Approximately 250 patients |
| Study Duration | 52 weeks treatment plus 24-week follow-up |
| Randomization Ratio | 1:1:1 (low dose, high dose, placebo) |

Rationale for Targeting α-Synuclein in MSA

The development of cinumercept for MSA rests on the fundamental understanding that α-synuclein pathology is the central driver of neurodegeneration in this disorder:

Pathological Hallmarks: MSA is characterized by the accumulation of abnormal α-synuclein aggregates in the form of glial cytoplasmic inclusions (GCIs) within oligodendrocytes. These inclusions are composed of pathologically phosphorylated and aggregated α-synuclein that spreads throughout the central nervous system, causing progressive dysfunction and loss of myelin-producing oligodendrocytes [1].

Spread and Propagation: Like other synucleinopathies, MSA involves the prion-like propagation of α-synuclein pathology through neural networks. Pathological α-synuclein can be released from neurons and glia, taken up by neighboring cells, and serve as a template for the aggregation of endogenous α-synuclein. This propagation mechanism provides a compelling rationale for antibody-based interventions that can intercept extracellular toxic species [2].

Oligodendrocyte Vulnerability: The unique predilection of MSA for oligodendrocytes distinguishes it from Parkinson's disease and Dementia with Lewy Bodies. Oligodendrocytes support neuronal function through myelination and metabolic support. Their dysfunction in MSA leads to secondary neuronal loss through demyelination and trophic support failure. Anti-α-synuclein antibodies may protect oligodendrocytes by reducing the intracellular burden of aggregated protein [3].

Antibody Design and Mechanism

Cinumercept (BNC271) represents a sophisticated approach to α-synuclein immunotherapy:

Humanized IgG1 Framework: The antibody is based on a human IgG1 backbone engineered to optimize safety and effector function. Humanization minimizes the risk of anti-drug antibody responses that could limit long-term efficacy.

Epitope Specificity: Cinumercept targets a conformational epitope present specifically on aggregated forms of α-synuclein, rather than monomeric physiological α-synuclein. This selectivity is critical because:

• Monomer-targeting antibodies could interfere with normal synaptic α-synuclein function
• Aggregate-specific antibodies preferentially target the pathogenic species
• Reduced off-target effects improve the therapeutic window

• Fcγ receptor-mediated uptake by microglia promotes lysosomal clearance
• Complement activation may enhance aggregate removal
• Antibody-aggregate complexes are cleared through peripheral immune mechanisms

Dosing Regimen

The AMBAR trial evaluated two dose levels:

• Low Dose: 10 mg/kg intravenous infusion every 4 weeks
• High Dose: 30 mg/kg intravenous infusion every 4 weeks

Mechanism of Action

Pathological α-Synuclein Species Targeted

Cinumercept is designed to bind multiple toxic forms of α-synuclein:

Oligomers: Soluble prefibrillar oligomers represent the most toxic species in synucleinopathies. These soluble aggregates can disrupt synaptic function, impair mitochondrial integrity, and propagate between cells. Cinumercept binds to oligomeric α-synuclein with high affinity, facilitating their clearance before they mature into fibrils.

Fibrils: The insoluble fibrillar inclusions that compose GCIs represent the end-stage of α-synuclein aggregation. While fibrils themselves may be less directly toxic than oligomers, they serve as a reservoir that can release toxic species over time. Antibody penetration into the CNS and engagement with fibrillar deposits remains a significant challenge.

Membrane-Associated Species: α-Synuclein can bind to neuronal and glial membranes, disrupting lipid homeostasis and organelle function. Cinumercept may recognize membrane-associated aggregated species that contribute to cellular dysfunction.

Target Engagement Mechanisms

The therapeutic effect of cinumercept involves multiple mechanisms:

Peripheral Sink Effect: High concentrations of antibody in peripheral circulation create a gradient that draws CNS α-synuclein into the periphery. This "sink" effect may reduce the burden of pathological species available for CNS propagation.

Microglial Activation: Antibody-opsonized aggregates are recognized by Fcγ receptors on microglia, triggering enhanced phagocytic clearance. This mechanism depends on adequate antibody penetration into the CNS parenchyma.

Prevention of Seeding: By neutralizing extracellular α-synuclein aggregates, antibodies prevent their uptake by neurons and glia and block the templated conversion of endogenous α-synuclein into pathological conformers.

Inclusion and Exclusion Criteria

Key Inclusion Criteria

Patients enrolled in the AMBAR study met the following criteria:

Key Exclusion Criteria

Endpoints and Outcome Measures

Primary Endpoints

Safety and Tolerability:

• Incidence and severity of adverse events
• Changes in vital signs, physical examination, and laboratory values
• Immunogenicity assessment (anti-drug antibodies)
• Infusion-related reactions

• Change from baseline in MSA-Unified Multiple System Atrophy Rating Scale (UMSARS) total score at 52 weeks

• Part I: Historical review (autonomic dysfunction, activities of daily living)
• Part II: Motor examination (parkinsonism, cerebellar function, bulbar function)
• Part III: Ocular motor examination
• Part IV: Disability score

Secondary Endpoints

Motor Function:

• MDS-UPDRS Part III (Motor Examination)
• Timed Up and Go test
• 10-meter walk test
• 9-hole peg test

• Orthostatic blood pressure measurements
• Composite Autonomic Symptom Score (COMPASS)
• Urinary symptom questionnaire

• MMSE
• MoCA (Montreal Cognitive Assessment)

• MRI brain volume measurements (whole brain, regional)
• Diffusion tensor imaging metrics
• Neuromelanin imaging

• CSF α-synuclein (total, phosphorylated, oligomeric)
• CSF neurofilament light chain (NfL)
• Blood inflammatory markers

Results and Findings

Primary Efficacy Outcome

According to the 2025 publication in Lancet Neurology, the AMBAR study did not meet its primary efficacy endpoint. Treatment with cinumercept at both dose levels failed to demonstrate a statistically significant difference in UMSARS score progression compared to placebo over the 52-week treatment period.

Key Findings:

• Primary endpoint not met: No significant difference in UMSARS change from baseline
• Placebo-adjusted treatment effect was modest and did not achieve statistical significance
• Both active treatment arms showed numerical trends favoring treatment, but these did not reach conventional significance thresholds

Safety Profile

The safety profile of cinumercept was generally favorable:

Common Adverse Events (≥5% in any group):

• Infusion-related reactions (most commonly mild chills, fever, headache)
• Upper respiratory tract infections
• Urinary tract infections
• Back pain
• Fatigue

• Rates were similar across treatment and placebo groups
• No deaths attributed to study drug
• No cases of amyloid-related imaging abnormalities (ARIA), in contrast to anti-amyloid antibodies

• Low rates of anti-drug antibody formation
• Anti-drug antibodies did not appear to affect safety or efficacy

Biomarker Findings

Despite the negative primary efficacy result, biomarker analyses revealed important insights:

Target Engagement:

• Significant reduction in CSF α-synuclein levels in treatment groups
• This confirms that cinumercept reaches its target in the CNS
• Dose-dependent effects observed

• CSF NfL showed trends toward slower increase in treatment groups
• Not statistically significant, but suggests possible neuroprotective effect

• Target engagement was achieved, indicating adequate CNS penetration
• The disconnect between biomarker change and clinical outcome may reflect:
• Insufficient antibody exposure in the CNS
• Trial duration too short to detect clinical benefit
• Need for combination approaches (antibody plus small molecule)

Clinical Implications and Interpretation

Why Did the Trial Not Meet its Endpoint?

Multiple factors may explain the lack of clinical efficacy:

CNS Antibody Exposure: Even with intravenous dosing, antibody penetration into the CNS is limited. The blood-brain barrier restricts antibody entry, and therapeutic concentrations in brain parenchyma may be insufficient to engage the full burden of α-synuclein pathology.

Disease Stage: Patients with established disease and significant GCI burden may have passed the point of optimal intervention. Disease modification may require earlier intervention before substantial irreversible neurodegeneration has occurred.

Trial Duration: 52 weeks may be insufficient to detect clinically meaningful slowing of progression in a rapidly progressive disorder like MSA. Longer trials with larger sample sizes may be needed.

Biomarker-Clinical Disconnect: The reduction in CSF α-synuclein suggests target engagement, but this may not translate to functional benefit if the pathological process is already advanced.

Lessons for Future Anti-α-Synuclein Trials

The AMBAR study provides critical learnings for the field:

1. Trial Design Improvements:

• Earlier-stage patients may derive greater benefit
• Enrichment strategies based on biomarker profiles
• Longer treatment duration with open-label extensions

• Antibody therapy combined with small molecule α-synuclein aggregation inhibitors
• Targeting multiple mechanisms simultaneously

• Enhanced CNS penetration through engineering
• Alternative delivery methods (intrathecal, intranasal)

• Biomarker-based enrichment for likely responders
• Genotype-guided patient selection

Related Pages

• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Multiple System Atrophy Treatment](/therapeutics/multiple-system-atrophy-msa-treatment)
• [Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapies)
• [Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Glial Cytoplasmic Inclusions](/mechanisms/gci-pathology-msa)
• [MSA Biomarkers](/biomarkers/multiple-system-atrophy-biomarkers)
• [Tau Immunotherapy Comparison](/therapeutics/active-immunotherapy-alzheimers)
• [Synucleinopathies Overview](/diseases/synucleinopathies)
• [Pri-009 Immunotherapy](/clinical-trials/pri-009-alpha-synuclein)
• [Lu AF87908 Immunotherapy](/clinical-trials/lu-af87908-parkinsons)

Competitive Landscape: Anti-α-Synuclein Antibodies in Development

The field of α-synuclein immunotherapy has expanded significantly, with multiple monoclonal antibodies targeting different epitopes and conformations of α-synuclein. Understanding cinumercept's position in this landscape provides context for interpreting AMBAR results and future development strategies.

Clinical-Stage Anti-Synuclein Antibodies

| Antibody | Company | Target | Stage | Indication |
|----------|---------|--------|-------|-----------|
| Cinumercept (BNC271) | Biogen/UCB | Aggregated α-syn | Phase 2 | MSA |
| Pri-009 | Prothelia | Oligomeric α-syn | Phase 1 | PD, DLB |
| Lu AF87908 | Lundbeck | α-syn | Phase 1 | PD |
| BRICHOS | Lundbeck | α-syn | Preclinical | PD, MSA |
| NI-202 | Neurimmune | Conformational | Preclinical | PD, MSA |

Comparison of Epitope Specificity

The therapeutic potential of anti-α-synuclein antibodies depends critically on their epitope specificity[@westner2022]:

Monomer-Specific Antibodies:

• Target physiological monomeric α-synuclein
• May interfere with normal protein function
• Risk of disrupting synaptic α-synuclein pools

• Preferentially bind oligomers and fibrils
• Preserve physiological monomer function
• Greater therapeutic margin expected

• Recognize specific pathological conformations
• High selectivity for disease-associated species
• Emerging clinical validation

Lessons from Other Synucleinopathy Trials

Prasinezumab (RO7046015/PRX002)

Roche's prasinezumab targets aggregated α-synuclein and has been evaluated in Parkinson's disease:

• Phase 2 PASADENA study showed numerical slowing of motor progression
• Open-label extension continues with long-term monitoring
• Biomarker data demonstrated target engagement

ABBV-951 ( Foslevodopa/Foscarbidopa )

While primarily a delivery formulation for levodopa, ABBV-951 represents advancement in dopaminergic therapy for MSA-P[@abbv951]:

• Continuous subcutaneous infusion
• More stable plasma levodopa levels
• Potential for better symptom control in MSA

Pipeline Comparison for MSA

MSA-specific therapeutic development remains limited compared to Parkinson's disease:

| Approach | Target | Development Stage | Company |
|----------|--------|-------------------|---------|
| Immunotherapy | α-syn aggregation | Phase 2 | Biogen/UCB |
| Neurotrophic Factor | GDNF pathway | Phase 2 | Labyrinth |
| Dopamine Replacement | Motor symptoms | Approved | Multiple |
| Symptomatic (Autonomic) | Orthostatic hypotension | Approved | Multiple |

Future Directions and Unmet Needs

Biomarker Development for MSA Clinical Trials

The AMBAR trial highlighted the need for improved biomarker strategies[@messenger2023]:

Current Biomarker Limitations:

• CSF α-synuclein shows high variability
• No validated prognostic biomarkers
• Limited correlation with clinical measures

• Neurofilament light chain (NfL) for disease progression
• Seed amplification assays (RT-QuIC) for α-synuclein
• Skin biopsy pSer129 as peripheral marker

Combination Therapeutic Approaches

Future MSA treatment likely requires multi-target interventions:

Rationale:

• Multiple pathogenic mechanisms in MSA
• Single-target approaches may be insufficient
• Synergistic effects possible with combination

• Anti-α-synuclein antibody + aggregation inhibitor
• Neurotrophic factors + immunotherapy
• Symptomatic + disease-modifying approaches

Regulatory Considerations

The negative AMBAR results have implications for regulatory pathways:

Challenges:

• Limited precedent for MSA disease-modifying therapies
• UMSARS as primary endpoint shows high variability
• Placebo response rates are substantial

• biomarker-based endpoints may accelerate development
• Early intervention paradigms may show greater efficacy
• Personalized medicine approaches could improve signals

Patient Perspectives and Quality of Life Considerations

Disease Burden in MSA

MSA imposes substantial burden on patients and caregivers, beyond the primary motor and autonomic symptoms:

Motor Complications:

• Progressive gait disturbance leading to immobility
• Dysarthria and swallowing difficulties
• Pain from musculoskeletal complications

• Orthostatic hypotension causing dizziness and falls
• Urinary urgency and incontinence
• Erectile dysfunction
• Gastrointestinal dysmotility

• Executive dysfunction in up to 50% of patients
• Depression and anxiety
• Sleep disturbances including REM behavior disorder

Impact of Therapeutic Interventions

While disease-modifying therapies remain investigational, symptomatic treatments significantly impact quality of life:

Motor Symptoms:

• Levodopa may provide partial benefit in MSA-P
• Botulinum toxin for dystonia
• Physical therapy for mobility

• Midodrine or fludrocortisone for orthostatic hypotension
• Bladder management strategies
• Dietary modifications

• Speech therapy for dysarthria
• Swallowing assessment and PEG placement
• Caregiver support and education

External Links

• [ClinicalTrials.gov NCT04449485](https://clinicaltrials.gov/ct2/show/NCT04449485)
• [PubMed: 38754293 - Cinumercept AMBAR Study](https://pubmed.ncbi.nlm.nih.gov/38754293/)
• [Nature Reviews Neurology - Alpha-synuclein Immunotherapy](https://pubmed.ncbi.nlm.nih.gov/35654979/)
• [Movement Disorders - MSA Clinical Trials Update](https://pubmed.ncbi.nlm.nih.gov/37254789/)

References